Blue Owl Capital backed the $4bn acquisition of PCI Pharma Services, a leading provider of pharmaceutical packaging and clinical trial solutions.
The deal was led by Kohlberg & Company, with Blue Owl providing strategic financing to support the transaction.
PCI Pharma Services, headquartered in Philadelphia, delivers packaging, clinical trial support, and supply chain solutions to pharmaceutical and biotech companies. Operating across the US, Europe, and Asia, PCI plays a vital role in accelerating drug development and ensuring timely delivery to patients worldwide.
The acquisition highlights the increasing demand for efficient pharmaceutical supply chain solutions amid growing global healthcare needs. Blue Owl’s investment aligns with its strategy to support resilient businesses in essential sectors, reflecting the firm’s confidence in PCI’s growth potential and its role in advancing global health innovation.
This transaction underscores the importance of strategic partnerships between private equity firms and alternative asset managers in funding large-scale deals within critical industries. Blue Owl’s involvement reaffirms its position as a trusted partner for transformative investments in high-growth sectors.
Source: Private Equity Wire
Can’t stop reading? Read more
Maximizing value creation in long-hold private equity investments
Maximizing value creation in long-hold private equity investments The private equity playbook is...
Clearlake, EQT, and Apollo among private equity bidders circling $3bn logistics firm Forward Air
Clearlake, EQT, and Apollo among private equity bidders circling $3bn logistics firm Forward Air...
France’s FRR launches €500m private equity fund-of-funds mandate with focus on domestic growth
France’s FRR launches €500m private equity fund-of-funds mandate with focus on domestic growth...